JW Therapeutics-B (02126): Carteyva (relma-cel injection) included in the National Basic Medical Insurance Drug Catalog

Zhitong Finance APP News, JW Therapeutics-B (02126) announces that the company's core product Carteyva (relma-cel injection) has been officially included in the 2026 edition of the National Reimbursement Drug List (NRDL). Starting from January 1, 2027, patients who fall within the national medical insurance payment scope and use Carteyva may enjoy basic medical insurance reimbursement in accordance with regulations. This medical insurance payment scope covers the three approved indications of Carteyva, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The price of Carteyva upon inclusion in the National Reimbursement Drug List is RMB 288,600.